Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | TGM2 | P21980 | 5/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600836 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29400961 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL178701 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29391986 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29958970 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL25358347 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29350360 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL178771 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL21462054 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL25356530 | 0.99 | KMT2A (0.59) | KMT2AMDM2TGM2TLR2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285600-A | Synthesis method of ganirelix acetate | 翰宇药业（武汉）有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-113354709-B | Solid phase synthesis method of metastatic prostate cancer targeting drug precursor | 江苏华益科技有限公司 | 2023-06-09 | — | — | CN | claimed |
| WO-2026098617-A1 | RADIOPHARMACEUTICAL TARGETING CARBONIC ANHYDRASE IX PROTEIN | 无锡诺宇医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | NORROY BIOSCIENCE CO LTD (CN) | 2026-05-14 | — | — | US | disclosed |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4637826-A1 | CONJUGATE COMPOUNDS AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS | Technische Universität München (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-12152089-B2 | LHRH-platinum conjugates for treating reproductive cancers | Eastern Kentucky University (US) | 2024-11-26 | — | — | US | disclosed |
| CN-118878637-A | Cyclic hexapeptide analogue serving as mu-opioid receptor antagonist as well as preparation and application thereof | 兰州大学 | 2024-11-01 | — | — | CN | disclosed |
| CN-118834271-A | Cyclic hexapeptide analogue containing aromatic structure amino acid at 3 sites and preparation and application thereof | 兰州大学 | 2024-10-25 | — | — | CN | disclosed |
| CN-118812662-A | Method for preparing ganirelix acetate | 杭州昊肽生物科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-115073556-A | Opioid/neuropeptide FF receptor multi-target cyclic peptide molecule and preparation and application thereof | 上海天慈生命科学发展有限公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2022188628-A1 | MULTI-TARGET CYCLOPEPTIDE MOLECULE FOR OPIOID/NEUROPEPTIDE FF RECEPTORS, AND PREPARATION THEREFOR AND APPLICATION THEREOF | 上海天慈生命科学发展有限公司 | 2022-09-15 | — | — | WO | disclosed |
| CN-115043904-A | Long-acting K opioid receptor agonist | 成都奥达生物科技有限公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022187216-A1 | SYNTHESIS OF GAMMA PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS, AND APPLICATIONS THEREFOR | CARNEGIE MELLON UNIVERSITY (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| EP-4048311-A1 | NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTIBODY 38C2 | University of Florida Research Foundation, Incorporated (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220193123-A1 | LHRH-PLATINUM CONJUGATES FOR TREATING REPRODUCTIVE CANCERS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2022-06-23 | — | — | US | disclosed |
| CN-111978371-B | Polypeptide derivative and application thereof in field of medicine | 成都诺和晟泰生物科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | CA9, CA11, CA12 | KMT2A 3456/4885MDM2 4177/4885TGM2 841/4885 |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | ERBB2, EGFR, ERBB3 | KMT2A 3524/4885MDM2 673/4885TGM2 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.